HYBRID EVENT: You can participate in person at Paris, France or Virtually from your home or work.

2nd Edition of International Heart Congress

June 20-22,2024 | Hybrid Event

June 20 -22, 2024 | Paris, France
Heart Congress 2024

Rationale for the prevention or therapy of sudden cardiac death in heart failure

Naranjan S Dhalla, Speaker at Heart Conferences
St. Boniface Hospital Albrechtsen Research Centre, Canada
Title : Rationale for the prevention or therapy of sudden cardiac death in heart failure


Although sudden cardiac death is considered to be a major mode of death in patients with heart failure, no satisfactory medical therapy is available for its prevention. Since over activation of sympathetic nervous system is invariably seen in subjects with high risk for sudden cardiac death, elevated levels of circulating catecholamine levels are considered to result in lethal ventricular arrhythmias and subsequent sudden cardiac death. However, experimental evidence from our laboratory has revealed that excessive amounts of circulating catecholamines are oxidized to aminochromes, which are highly reactive quinine compounds, in addition to producing oxidative stress. A marked increase in plasma adrenochrome level was seen in heart failure; patients with higher than mean value for adrenochrome showed greater mortality. An antiplatelet agent, sulfinpyrazone, was observed to depress the adrenochrome- induced incidence of arrhythmias as well as mortality of animals. The oxidation products of catecholamines (both adrenochrome and oxidative stress) have been demonstrated to produce subcellular alterations, intracellular Ca2+-overload, coronary spasm, myocardial cell damage, depletion of high energy stores and ventricular arrhythmias. Furthermore, catecholamine-induced arrhythmias and ventricular fibrillation were associated with elevated levels of plasma adrenochromes and these changes were markedly attenuated by treatment of animals with different antioxidants. The results suggest that oxidation of catecholamines under stressful conditions may play a critical role in the genesis of fatal ventricular arrhythmias. Accordingly, antioxidant therapy in heart failure may be helpful in preventing sudden cardiac death.


Naranjan S. Dhalla is a Distinguished Professor at the University of Manitoba and was the founding Director of the Institute of Cardiovascular Sciences and served for 19 years. He is currently serving as Executive Director of the International Academy of Cardiovascular Sciences and has been elected its Honorary Life President. He served for 36 years as Editor-in-Chief of a major medical journal, Molecular and Cellular Biochemistry. He was both Secretary General and President of the International Society for Heart Research for more than 25 years. His research in the field of cardiovascular pathophysiology over the years has had a major impact on the understanding of heart disease and its treatment. He has published more than 875 full length papers and reviews, and has edited or authored over 68 books. Dr. Dhalla has received 216 honours and awards including Fellowship of the Royal Society of Canada, Membership of the Order of Canada and Order of Manitoba, Honorary Degrees and Professorships from 12 Universities, Medal of Honour of the Canadian Medical Association and Research Achievement Award of the Canadian Cardiovascular Society, and has been inducted in the Citizen Hall of Fame in Winnipeg as well as Canadian Medical Hall of Fame.